Adeyemi Wale J, Olayaki Luqman A
Department of Physiology, College of Health Sciences, University of Ilorin, Ilorin, Nigeria.
Chin J Physiol. 2019 May-Jun;62(3):108-116. doi: 10.4103/CJP.CJP_8_18.
Reports on the coexistence of diabetes mellitus and osteoarthritis in human subjects dated back to the 1960s. However, there is no account in literature on the co-manifestation of these disease conditions in experimental animals. In our previous study, we reported for the first time, the effects of pharmacological agents on glucoregulatory indices, lipid profile, and inflammatory markers in experimental diabetic-knee osteoarthritic rat. However, in the present study, the effects of salmon calcitonin (Sct), and/or omega-3 fatty acids (N-3) were further investigated on other biomarkers. Forty-nine rats of seven animals per group were used for this study. Diabetes was induced by the administration of streptozotocin (65 mg/kg) and nicotinamide (110 mg/kg). Thereafter, knee osteoarthritis was induced by the intra-articular injection of 4 mg of sodium monoiodoacetate in 40 μl of saline. Nine days after the inductions, treatments started, and they lasted for 4 weeks. N-3 was administered at 200 mg/kg/day, while Sct was administered at 2.5 and 5.0 IU/kg/day. The results of the study indicated that the induced diabetes-knee osteoarthritis caused significant alterations in all the observed biomarkers. Sct showed a dose-specific effect and an additive action with N-3 in reducing malondialdehyde and lactate dehydrogenase, and in elevating total bilirubin and total antioxidant capacity. However, it largely demonstrated a nondose-specific effect and nonadditive action with N-3 on superoxide dismutase, catalase, glutathione peroxidase, total alkaline phosphatase, c-telopeptide of type-I collagen, collagen type-2 alpha 1, and hematological indices. In conclusion, the combined administration of Sct and N-3 proffer better therapeutic effects than the single therapy; therefore, they could be used in the management of diabetic-osteoarthritic condition.
关于人类受试者中糖尿病与骨关节炎共存的报告可追溯到20世纪60年代。然而，文献中没有关于这些疾病状况在实验动物中共存表现的记载。在我们之前的研究中，我们首次报道了药物制剂对实验性糖尿病膝骨关节炎大鼠的血糖调节指标、血脂谱和炎症标志物的影响。然而，在本研究中，进一步研究了鲑鱼降钙素（Sct）和/或ω-3脂肪酸（N-3）对其他生物标志物的影响。本研究使用了49只大鼠，每组7只动物。通过注射链脲佐菌素（65mg/kg）和烟酰胺（110mg/kg）诱导糖尿病。此后，通过在40μl盐水中关节内注射4mg单碘乙酸钠诱导膝骨关节炎。诱导后9天开始治疗，持续4周。N-3以200mg/kg/天的剂量给药，而Sct以2.5和5.0IU/kg/天的剂量给药。研究结果表明，诱导的糖尿病膝骨关节炎导致所有观察到的生物标志物发生显著变化。Sct在降低丙二醛和乳酸脱氢酶以及提高总胆红素和总抗氧化能力方面显示出剂量特异性效应和与N-3的相加作用。然而，在超氧化物歧化酶、过氧化氢酶、谷胱甘肽过氧化物酶、总碱性磷酸酶、I型胶原的c-末端肽、2型胶原α1和血液学指标方面，它在很大程度上表现出非剂量特异性效应和与N-3的非相加作用。总之，Sct和N-3联合给药比单一疗法具有更好的治疗效果；因此，它们可用于糖尿病骨关节炎病症的管理。
